Search

Search Constraints

You searched for: Author/Creator Kramer, Lynn D

Search Results

1. AHEAD 3‐45 study design: A global study to evaluate the efficacy and safety of treatment with BAN2401 for 216 weeks in preclinical Alzheimer's disease with intermediate amyloid (A3 trial) and elevated amyloid (A45 trial): Clinical trial design and implementation. (7th December 2020)

2. AHEAD 3‐45 study: Preliminary screening and baseline characteristics from a placebo‐controlled, double‐blind study evaluating lecanemab in participants with preclinical Alzheimer's disease and elevated (A45 trial) and intermediate (A3 trial) amyloid. (31st December 2021)

3. Baseline characteristics for CLARITY AD: A phase 3 placebo‐controlled, double‐blind, parallel‐group, 18‐month study evaluating lecanemab (ban2401) in early Alzheimer's disease. (31st December 2021)

5. Diversity in Phase 2 and Phase 3 Placebo‐Controlled, Double‐Blind, Lecanemab and Elenbecestat Early Alzheimer's Disease Studies. (20th December 2022)

6. Lecanemab (BAN2401) Infusion Reactions and Immunogenicity: Results from Randomized Phase 2 Study and an Open‐Label Extension (OLE). (20th December 2022)

7. Plasma Aβ 42:40 ratio tracks with changes in brain amyloid PET SUVr in the core and open label extension of the phase 2 proof of concept study ban2401‐g000‐201 following treatment with lecanemab in subjects with early Alzheimer's disease. (31st December 2021)

8. Preliminary assessment of the clinical effects of lecanemab following 18 months of treatment in the open label extension of the phase 2 proof of concept study, BAN2401‐G000‐201, in subjects with early Alzheimer's disease. (31st December 2021)

9. Preliminary assessment of the clinical effects of lecanemab following 18 months of treatment in the open label extension of the phase 2 proof of concept study, BAN2401‐G000‐201, in subjects with early Alzheimer's disease. (31st December 2021)

10. Strategies for diverse participant recruitment to a preclinical Alzheimer's Disease prevention trial: The AHEAD study. (20th December 2022)